Reglagene is advised by drug discovery and development professionals with exceptional track records of advancing new cancer medicines into the clinic and onto the market.
DAVID BEARSS, PhD
Dr. David Bearss is the CEO at Tolero Pharmaceuticals in Salt Lake City, Utah. He brings a consistent and successful track record of drug discovery and development that spans the last 17 years in both academic and industrial settings. Dr. Bearss is an expert in small-molecule drug development and in the use of genetic model systems in drug discovery, and he has deep experience in translational research focused on drug development and the use of genetic markers to predict drug sensitivity. He is also an expert in the development and use of genetically modified animals to model human disease. Dr. Bearss received his PhD in Cell and Structural Biology at the University of Texas Health Sciences Center at San Antonio and was a postdoctoral fellow with Dr. Daniel Von Hoff, a recognized leader in drug development. Dr. Bearss was on the faculty at the University of Arizona from 1999 to 2003, after which he co-founded Montigen Pharmaceuticals in 2003, where he served as Chief Scientific Officer until Montigen was acquired by SuperGen (Nasdaq: SUPG) in 2006. Dr. Bearss served as Chief Scientific Officer at SuperGen, overseeing early drug discovery and development, and subsequently as Co-Director of the Center for Investigational Therapeutics at the Huntsman Cancer Institute, Associate Professor in the Department of Oncological Sciences at the University of Utah, and Associate Professor of Physiology & Developmental Biology at Brigham Young University prior to cofounding Tolero. Dr. Bearss has published more than 70 manuscripts and book chapters, has more than 30 patents issued or pending, and has won several awards for his scientific achievements. Dr. Bearss recently led Tolero to a successful $630M exit in an acquisition by Sumitomo Dainippon.
MARK CHAPMAN, PhD
Dr. Mark Chapman is a veteran of large and small biotech companies. He is well versed in all aspects of drug discovery, including target selection, validation, screening, hit-to-lead, lead optimization, preclinical testing, candidate selection, and early clinical development. He has worked with small molecules as well as therapeutic antibodies. Dr. Chapman has led cross-functional teams; established partnerships with CROs, clinicians, and academic groups; and is adept at addressing key questions in a cost-effective manner. He has deep knowledge in oncology and has additional experience in endocrinology and immunology. He holds a BA in genetics (UC Berkeley) and a PhD in Biochemistry (University of Arizona), and he trained at the Salk Institute.
Jim Heddles has 30 years of experience in preclinical drug discovery computing, having led infrastructure and scientific projects and teams within Sanofi and its predecessor companies. Jim most recently had the privilege of leading a phenomenal IT/Informatics team through a complete rebuild of architecture, systems, and applications after the acquisition of the Sanofi Tucson facility by Icagen. His passion is to help companies understand their workflows and data needs and adopt the most appropriate tools to enable excellent decision making for drug discovery.
MATTHEW MARX, PhD
Dr. Matthew Marx is the principal at Marx Pharma, LLC, and a medicinal chemist with nearly 20 years of industry experience, mostly in the oncology therapeutic area. As a project scientist, project leader, or department head, he has been responsible for over 20 development candidates (Regulatory Toxicology candidates) and a dozen Initial New Drug applications. He completed his PhD in Organic Chemistry at the University of California at Berkeley and postdoctoral work at the University of Texas at Austin. His prior roles include Head of Oncology Chemistry at Pfizer’s Groton, CT site (1998–2010) and Chemistry Department Head at Takeda California (2010–2015). Dr. Marx currently is Vice President of Discovery Chemistry for Mirati Therapeutics in San Diego. He is widely regarded in the Medicinal Chemistry community and is the outgoing chair of the Medicinal Chemistry Gordon Research Conference.
CELINA ZERBINATTI, PhD
Dr. Celina Zerbinatti joined Reglagene as a Senior Consultant in December 2019, bringing expertise in the area of neurodegenerative diseases, together with more than 15 years of pharma experience in assay development, disease models, and biomarker discovery. Dr. Zerbinatti was most recently Vice President, Head of Biology at E-Scape Bio, a biotech company developing small-molecule therapeutics for genetically driven neurodegenerative diseases. Before E-Scape, Dr. Zerbinatti was a consultant with the Dementia Discovery Fund, where she developed early seed projects for NewCo creation and supported assessment of new investment opportunities. Prior to her roles in biotech and venture, Dr. Zerbinatti was Vice President, Neurobiology at Evotec, overseeing the operational and scientific efforts of a broad drug discovery alliance with the CHDI Foundation on Huntington’s disease. She also played a role in advancing early-stage programs within the internal Neuroscience R&D portfolio at Evotec Innovate. Dr. Zerbinatti gained extensive experience in drug discovery at Merck Research Laboratories. As Associate Director in the Neuroscience Department, she led multiple target validation efforts, as well as preclinical drug discovery teams, focusing on targets genetically linked to Alzheimer’s and other neurodegenerative diseases. Dr. Zerbinatti obtained her BS, MS, and PhD at the University of Sao Paulo, Brazil, and completed her postdoctoral training in the field of neurodegeneration at Washington University School of Medicine in Saint Louis, MO.
DANIEL VON HOFF, MD, FACP
Dr. Daniel Von Hoff, MD, FACP, is Physician-in-Chief and Distinguished Professor of Translational Research at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. He is also Senior Consultant, Clinical Investigations for the City of Hope; Chief Scientific Officer for HonorHealth Research Institute; Medical Director of Research, Chief Scientific Officer, US Oncology; and Professor of Medicine, Mayo Clinic. Dr. Von Hoff’s major interest is in the development of new anticancer agents, in both the clinic and the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely, including mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegib, nab-paclitaxel, nal-IRI, and others. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies for patients with pancreatic and other advanced cancers. Dr. Von Hoff has published more than 690 papers, 140 book chapters, and over 1400 abstracts. He received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care. Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board (2004–2010). He is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX Oncology, Inc. (acquired by Genzyme after ILEX had two agents, alemtuzumab and clofarabine, approved by the FDA for patients with leukemia). Dr. Von Hoff is founder and Editor Emeritus of Investigational New Drugs, The Journal of New Anticancer Agents and past Editor-in-Chief of Molecular Cancer Therapeutics. He is a cofounder of the AACR/ASCO Methods in Clinical Cancer Research Workshop. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology, graduate students, and postdoctoral fellows.
1703 E Mabel St | Tucson, AZ 85721 | USA